A Coactivator Role of CARM1 in the Dysregulation of beta-Catenin Activity in Colorectal Cancer Cell Growth and Gene Expression

作者：Ou Chen Yin; LaBonte Melissa J; Manegold Philipp C; So Alex Yick Lun; Ianculescu Irina; Gerke Daniel S; Yamamoto Keith R; Ladner Robert D; Kahn Michael; Kim Jeong Hoon; Stallcup Michael R^*

来源：Molecular Cancer Research, 2011, 9(5): 660-670.

DOI：10.1158/1541-7786.MCR-10-0223

Aberrant activation of Wnt/beta-catenin signaling, resulting in the expression of Wnt-regulated oncogenes, is recognized as a critical factor in the etiology of colorectal cancer. Occupancy of beta-catenin at promoters of Wnt target genes drives transcription, but the mechanism of beta-catenin action remains poorly understood. Here, we show that CARM1 (coactivator-associated arginine methyltransferase 1) interacts with beta-catenin and positively modulates beta-catenin-mediated gene expression. In colorectal cancer cells with constitutively high Wnt/beta-catenin activity, depletion of CARM1 inhibits expression of endogenous Wnt/beta-catenin target genes and suppresses clonal survival and anchorage-independent growth. We also identified a colorectal cancer cell line (RKO) with a low basal level of beta-catenin, which is dramatically elevated by treatment with Wnt3a. Wnt3a also increased the expression of a subset of endogenous Wnt target genes, and CARM1 was required for the Wnt-induced expression of these target genes and the accompanying dimethylation of arginine 17 of histone H3. Depletion of beta-catenin from RKO cells diminished the Wnt-induced occupancy of CARM1 on a Wnt target gene, indicating that CARM1 is recruited to Wnt target genes through its interaction with beta-catenin and contributes to transcriptional activation by mediating events (including histone H3 methylation) that are downstream from the actions of beta-catenin. Therefore, CARM1 is an important positive modulator of Wnt/beta-catenin transcription and neoplastic transformation, and may thereby represent a novel target for therapeutic intervention in cancers involving aberrantly activated Wnt/beta-catenin signaling. Mol Cancer Res; 9(5); 660-70.

• 出版日期2011-5